Join
Live feed
·
PRReleasevia Quantisnow
Aileron Therapeutics Inc. logo

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

ByQuantisnow·Wall Street's wire, on your screen.
ALRN· Aileron Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALRN (Aileron Therapeutics Inc.) and more on Quantisnow.